Aditya Mishra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aditya Mishra has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Achal Mishra
Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur 495009, Chhattisgarh, India
1 shared publication - Andréia Bagliotti Meneguin
Department of Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara 14800-903, Brazil
1 shared publication - Cesar Augusto Roque-Borda
Vicerrectorado de Investigación, Universidad Catolica de Santa María, Arequipa, Perú
1 shared publication - Fernando Rogério Pavan
Tuberculosis Research Laboratory School of Pharmaceutical Sciences São Paulo State University (UNESP) Araraquara Brazil
1 shared publication - Oswaldo Julio Ramirez Delgado
Tuberculosis Research Laboratory, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara 14800-903, Brazil
1 shared publication - Subham Kumar Vishwakarma
Tuberculosis Research Laboratory, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara 14800-903, Brazil
1 shared publication
Latest Publications
- Open Access
- 24 March 2026
- Published by MDPI AG in Future Pharmacology
- Vol. 6 (2) , 18
Structure-Based Virtual Screening in Tuberculosis Drug Discovery Pharmacological Constraints Failure Modes and Translational Lessons
Structure-based strategies are widely used in tuberculosis drug discovery; however, their translational impact remains limited. This review examines how structure-based virtual screening (SBVS) is applied in practice to Mycobacterium tuberculosis targets and explores why docking-derived predictions frequently fail to translate into measurable biological activity. Rather than treating docking scores as quantitative predictors of potency, representative case studies are analyzed to demonstrate that SBVS is most effective when employed as a prioritization framework integrated with appropriate target preparation, physicochemical filtering, and early experimental validation. Across diverse targets, molecular dynamics simulations emerge as a critical discriminator, enabling the identification of binding instability and false-positive hits that persist after static docking. Tuberculosis-specific constraints—including cofactor-dependent catalysis, resistance-associated mutations, membrane-rich environments, and permeability barriers—are discussed as key factors decoupling in silico affinity from whole-cell efficacy. Collectively, these observations support a workflow-oriented view of computational drug discovery in tuberculosis, in which iterative integration of structural modeling and experimental validation is required for meaningful lead identification.
- 24 March 2026
- Published by MDPI AG in Future Pharmacology
- Vol. 6 (2) , 18
Open AccessStructure-Based Virtual Screening in Tuberculosis Drug Discovery Pharmacological Constraints Failure Modes and Translational Lessons
Structure-based strategies are widely used in tuberculosis drug discovery; however, their translational impact remains limited. This review examines how structure-based virtual screening (SBVS) is applied in practice to Mycobacterium tuberculosis targets and explores why docking-derived predictions frequently fail to translate into measurable biological activity. Rather than treating docking scores as quantitative predictors of potency, representative case studies are analyzed to demonstrate that SBVS is most effective when employed as a prioritization framework integrated with appropriate target preparation, physicochemical filtering, and early experimental validation. Across diverse targets, molecular dynamics simulations emerge as a critical discriminator, enabling the identification of binding instability and false-positive hits that persist after static docking. Tuberculosis-specific constraints—including cofactor-dependent catalysis, resistance-associated mutations, membrane-rich environments, and permeability barriers—are discussed as key factors decoupling in silico affinity from whole-cell efficacy. Collectively, these observations support a workflow-oriented view of computational drug discovery in tuberculosis, in which iterative integration of structural modeling and experimental validation is required for meaningful lead identification.